Advanced search

Vol 9, No 1 (2018)
Review paper
Published online: 2018-05-23

open access

View PDF (Polish) Download PDF file
Page views 826
Article views/downloads 3887
Get Citation

Connect on Social Media

Connect on Social Media

The most important changes in the diagnosis of aggressive B cell lymphomas according to the World Health Organization 2017 classification

Anna Szumera-Ciećkiewicz1, Monika Prochorec-Sobieszek1
DOI: 10.5603/Hem.2018.0001
Hematologia 2018;9(1):1-14.

Abstract

In 2017, the revised 4th edition of the classification of tumors of hematopoietic and lymphoid tissues developed by the World Health Organization was introduced. Some of the significant changes concern the updating of data covering biology, pathomorphology, genetics and clinical features of aggressive lymphomas from mature B cells. New entities have been introduced (high grade B-cell lymphoma and Burkitt-like lymphoma with 11q aberration), some of existing ones have beenmodified (EBV-positive diffuse large B-cell lymphoma, not otherwise specified) and some provisional ddefinitions (unclassified B-cell lymphoma, with intermediate features between diffuse B-cell lymphoma and classic Hodgkin’s lymphoma) have been retained. Significant progress in the field of molecular biology techniques and genetics translates into their practical use in the routine diagnosis of lymphomas. Currently, the correct diagnosis of high-grade B-cell lymphoma in addition to pathomorphological and immunohistochemical diagnosis requires the determination of status C-MYC, BCL2 and BCL6 genes. This is a significant challenge for the reorganization of routine diagnostics. This is influenced by limited availability of standardized molecular/genetic techniques and determination of funding for these studies. The most important factor still remaining is the involvement of a specialized team of doctors and technicians ensuring adequate collection, protection of biological material and its development by various techniques, which translates into the possibility of issuing a full result including proper diagnosis.

Keywords: aggressive lymphomas from mature B cellsclassificationhistopathological diagnosismolecular biology and lymphoma genetics

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition): IARC: Lyon. 2017.
  2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
    CrossRefPubMed
  3. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017; 130(4): 410–423.
    CrossRefPubMed
  4. Johnsen HE, Bergkvist KS, Schmitz A, et al. Myeloma Stem Cell Network (MSCNET). Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. Leuk Lymphoma. 2014; 55(6): 1251–1260.
    CrossRefPubMed
  5. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018; 50(1): 74–87.
    CrossRefPubMed
  6. Ott G. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. Br J Haematol. 2017; 178(6): 871–887.
    CrossRefPubMed
  7. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014; 11(1): 12–23.
    CrossRefPubMed
  8. Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015; 52(2): 67–76.
    CrossRefPubMed
  9. Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011; 28(2): 167–177.
    PubMed
  10. Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015; 14: 207.
    CrossRefPubMed
  11. Chiappella A, Santambrogio E, Castellino A, et al. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Rev Hematol. 2017; 10(8): 697–705.
    CrossRefPubMed
  12. Warzocha K. Leczenie chorych na chłoniaki rozlane z dużych komórek B. Acta Haematologica Polonica. 2015; 46: 47.
    CrossRef
  13. Klapper W. Histopathology of mantle cell lymphoma. Semin Hematol. 2011; 48(3): 148–154.
    CrossRefPubMed
  14. Altenbuchinger M, Schwarzfischer P, Rehberg T, et al. Molecular signatures that can be transferred across different omics platforms. Bioinformatics. 2017; 33(14): i333–i340.
    CrossRefPubMed
  15. Yoon N, Ahn S, Yong Yoo H, et al. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Oncotarget. 2017; 8(13): 22014–22022.
    CrossRefPubMed
  16. Cheng CL, O'Connor S. T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach. J Clin Pathol. 2017; 70(3): 187–201.
    CrossRefPubMed
  17. Hartmann S. From a pathologist's point of view: Histiocytic cells in Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Pathol Res Pract. 2015; 211(12): 901–904.
    CrossRefPubMed
  18. Tousseyn T, De Wolf-Peeters C. T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification. Virchows Arch. 2011; 459(6): 557–563.
    CrossRefPubMed
  19. Martelli M, Ferreri AJM, Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2008; 68(3): 256–263.
    CrossRefPubMed
  20. Martelli M, Di Rocco A, Russo E, et al. Primary mediastinal lymphoma: diagnosis and treatment options. Expert Rev Hematol. 2015; 8(2): 173–186.
    CrossRefPubMed
  21. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017; 14(4): 203–220.
    CrossRefPubMed
  22. Yu Li, Li L, Medeiros LJ, et al. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev. 2017; 31(2): 77–92.
    CrossRefPubMed
  23. Patrick LB, Mohile NA. Advances in Primary Central Nervous System Lymphoma. Curr Oncol Rep. 2015; 17(12): 60.
    CrossRefPubMed
  24. Deckert M, Brunn A, Montesinos-Rongen M, et al. Primary lymphoma of the central nervous system--a diagnostic challenge. Hematol Oncol. 2014; 32(2): 57–67.
    CrossRefPubMed
  25. Deckert M, Montesinos-Rongen M, Brunn A, et al. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2014; 127(2): 175–188.
    CrossRefPubMed
  26. Sugita Y, Muta H, Ohshima K, et al. Primary central nervous system lymphomas and related diseases: Pathological characteristics and discussion of the differential diagnosis. Neuropathology. 2016; 36(4): 313–324.
    CrossRefPubMed
  27. Castillo JJ, Beltran BE, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(5): 529–537.
    CrossRefPubMed
  28. Ghosh Roy S, Robertson ES, Saha A. Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis. Biomolecules. 2016; 6(4).
    CrossRefPubMed
  29. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008; 83(10): 804–809.
    CrossRefPubMed
  30. Harmon CM, Smith LB. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis. Arch Pathol Lab Med. 2016; 140(10): 1074–1078.
    CrossRefPubMed
  31. Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011; 35(12): 1571–1577.
    CrossRefPubMed
  32. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004; 28(6): 736–747.
    PubMed
  33. Gonzalez-Farre B, Martinez D, Lopez-Guerra M, et al. HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Mod Pathol. 2017; 30(5): 745–760.
    CrossRefPubMed
  34. Montes-Moreno S, Montalbán C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma. 2012; 53(2): 185–194.
    CrossRefPubMed
  35. Pan Z, Hu S, Li M, et al. ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. Am J Surg Pathol. 2017; 41(1): 25–38.
    CrossRefPubMed
  36. Sakamoto K, Nakasone H, Togashi Y, et al. ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol. 2016; 103(4): 399–408.
    CrossRefPubMed
  37. Cai Q, Medeiros LJ, Xu X, et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015; 6(36): 38591–38616.
    CrossRefPubMed
  38. Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. Hematol Oncol Clin North Am. 2016; 30(6): 1333–1343.
    CrossRefPubMed
  39. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418): 116–120.
    CrossRefPubMed
  40. Iqbal J, Naushad H, Bi C, et al. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis? Blood Rev. 2016; 30(2): 73–88.
    CrossRefPubMed
  41. Lynch RC, Gratzinger D, Advani RH, et al. Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Curr Treat Options Oncol. 2017; 18(7): 45.
    CrossRefPubMed
  42. Grygalewicz B, Woroniecka R, Rymkiewicz G, et al. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS. Am J Clin Pathol. 2017; 149(1): 17–28.
    CrossRefPubMed
  43. Rymkiewicz G, Grygalewicz B, Chechlinska M, et al. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Mod Pathol. 2018 [Epub ahead of print].
    CrossRefPubMed
  44. Salaverria I, Martin-Guerrero I, Wagener R, et al. Molecular Mechanisms in Malignant Lymphoma Network Project, Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014; 123(8): 1187–1198.
    CrossRefPubMed
  45. Li S, Desai P, Lin P, et al. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016; 68(7): 1090–1098.
    CrossRefPubMed
  46. Li S, Weiss VL, Wang XJ, et al. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Am J Surg Pathol. 2016; 40(2): 253–261.
    CrossRefPubMed
  47. Pillai RK, Sathanoori M, Van Oss SB, et al. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013; 37(3): 323–332.
    CrossRefPubMed
  48. Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 90–99.
    CrossRefPubMed
  49. Yoshida M, Ichikawa A, Miyoshi H, et al. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. Pathol Int. 2015; 65(10): 519–527.
    CrossRefPubMed
  50. Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017; 129(3): 280–288.
    CrossRefPubMed
  51. Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017; 31(2): 37–42.
    CrossRefPubMed
  52. Campo E. MYC in DLBCL: partners matter. Blood. 2015; 126(22): 2439–2440.
    CrossRefPubMed
  53. Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012; 18(5): 411–420.
    CrossRefPubMed
  54. Rentas Torres Y, Rodríguez-López JL, Valentin M, et al. Difficult Diagnosis between B Cell Lymphoma and Classical Hodgkin's Lymphoma. Bol Asoc Med P R. 2015; 107(3): 98–101.
    PubMed
  55. Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126(7): 863–872.
    CrossRefPubMed
  56. Calvo KR, Traverse-Glehen A, Pittaluga S, et al. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol. 2004; 11(5): 227–238.
    PubMed
  57. Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007; 31(1): 106–112.
    CrossRefPubMed
  58. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011; 24(12): 1586–1597.
    CrossRefPubMed
  59. Evens AM, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015; 90(9): 778–783.
    CrossRefPubMed
  60. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015; 125(1): 33–39.
    CrossRefPubMed
  61. Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014; 124(10): 1563–1569.
    CrossRefPubMed
  62. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11): 3909–3918.
    PubMed
  63. Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017; 92(8): 806–813.
    CrossRefPubMed
  64. Beà S, Amador V. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. Curr Oncol Rep. 2017; 19(6): 43.
    CrossRefPubMed
  65. Lu TX, Li JY, Xu W. The role of SOX11 in mantle cell lymphoma. Leuk Res. 2013; 37(11): 1412–1419.
    CrossRefPubMed
  66. Zlamalikova L, Moulis M, Salek D, et al. Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas. Oncol Rep. 2016; 35(5): 2673–2680.
    CrossRefPubMed
  67. Dreyling M, Ferrero S, Vogt N, et al. European Mantle Cell Lymphoma Network. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014; 20(20): 5194–5206.
    CrossRefPubMed
  68. Martin P, Ghione P, Dreyling M. Mantle cell lymphoma - Current standards of care and future directions. Cancer Treat Rev. 2017; 58: 51–60.
    CrossRefPubMed
  69. Onaindia A, Medeiros LJ, Patel KP. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol. 2017; 30(10): 1338–1366.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Hematology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice